Parasite | Eso | Sto | Cancer | ESD
[Dr. Sinn's LiverTODAY 018 - Lexicon for HCC surveillance US - Clinical molecular hepatology]
´ëÇÑ°£ÇÐȸ¿¡¼ ¹ßÇàÇÏ´Â Clinical Molecular Hepatology 2017³â 3¿ùÈ£¿¡´Â NAFLD, cirrhosis anticoagulation, ÀÚ°¡¸é¿ª°£Áúȯ¿¡¼ÀÇ ¸é¿ª¾ïÁ¦Á¦ »ç¿ë µî¿¡ ´ëÇÑ Á¾¼³°ú, 6ÆíÀÇ ¿øÀú, 2ÆíÀÇ Áõ·Ê, 1ÆíÀÇ °£º´¸®, 1ÆíÀÇ °£¿µ»ó °ü·Ã ³»¿ëÀÌ ½Ç·È½À´Ï´Ù. ±× Áß ¿øÀú Áß ÇÑÆí ¼Ò°³ÇÏ·Á°í ÇÕ´Ï´Ù.
A lexicon for hepatocellular carcinoma surveillance ultrasonography: benign versus malignant lesions. An et al., Clin Mol Hepatol. 2017
175¸íÀÇ °£¾Ï À§ÇèÀÎÀÚ°¡ ÀÖ´Â ºÐµéÀÇ ¼±º°°Ë»ç·Î ½ÃÇàÇÑ ÃÊÀ½ÆÄ °Ë»ç »ó, ¾Ç¼ºÀ» ½Ã»çÇÏ´Â ¼Ò°ßÀÌ ¹«¾ùÀÎÁö »ìÆ캻 ¿¬±¸ÀÔ´Ï´Ù. ±× °á°ú larger tumor size, multinodular confluent morphology, thick hypoechoic rim, posterior acoustic enhancement µîÀÌ ¾Ç¼ºÀ» ½Ã»çÇÏ´Â ¼Ò°ßÀ̾ú½À´Ï´Ù. Å©±â°¡ Ŭ¼ö·Ï ¾Ç¼º °¡´É¼ºÀÌ ³ô¾ÒÀ¸¸ç, 2cmÀ̳»ÀÇ °áÀý¿¡¼´Â À§¿¡ ¾ð±ÞµÈ ÃÊÀ½ÆÄ ¼Ò°ßÀ¸·Î´Â ¾Ç¼º/¾ç¼ºÀ» ±¸ºÐÇÒ ¼ö ¾ø¾ú´Ù°í ÇÕ´Ï´Ù.
¾Æ·¡´Â ÃÊÀ½ÆÄ °Ë»ç»ó °áÀýÀÇ Æ¯Â¡À» ±â¼úÇÒ ¶§ ½áº¼ ¼ö ÀÖ´Ù°í Á¦¾ÈÇϽŠterminologyÀÔ´Ï´Ù.
[Comment]
ÃÊÀ½ÆÄ·Î HCC surveillance¸¦ ÇÏ´Â °ÍÀº °£¾ÏÀÇ °íÀ§Çè ȯÀںе鿡°Ô ±Ç°íµÇ°í ÀÖ½À´Ï´Ù. Àú´Â ÀÌ data¸¦ º¸¸é¼, HCC surveillance¿¡¼ ¹ß°ßµÈ °áÀýÀÇ Å©±â¿¡ ´õ Èï¹Ì°¡ ÀÖ¾ú½À´Ï´Ù. 2008~2014³âµ¿¾È HCC surveillance¸¦ ÇÏ´Â µ¿¾È¿¡, 512¸í¿¡¼ °£¿¡ ÀÇ½É °áÀýÀÌ ÀÖ¾ú´Âµ¥, ÀÌÁß 188°³ÀÇ ÃÊÀ½ÆÄ»ó ¹ß°ßµÈ °áÀý¿¡ ºÐ¼®ÀÔ´Ï´Ù. 87°³ÀÇ °áÀýÀº ¾Ç¼ºÀ̾ú½À´Ï´Ù. 87°³ÀÇ °áÀý Áß 14°³ÀÇ °áÀý¸¸ (16.0%) 2cm À̳»¿´°í, 2-3cm (34.4%), 3cmÀÌ»óÀÌ 49.4% ¿´½À´Ï´Ù. HCCÀÇ surveillance°¡ Á¶±â¿¡ ÀÛÀº °£¾ÏÀ» ã´Â °ÍÀ̶ó¸é, ¾à°£ ½Ç¸Á½º·¯¿î °á°úÀÔ´Ï´Ù. ¾ÏÀº ã¾ÒÁö¸¸, Á¶±â¿¡ ãÁö ¸øÇÑ´Ù¸é^^. ÃÊÀ½ÆÄ·Î HCC surveillance¸¦ ÇÒ ¶§¿¡´Â ÃÊÀ½ÆÄ HCC surveillanceÀÇ ÇѰ踦 Àß ÀÌÇØÇÏ°í ÀÖ´Â °ÍÀÌ Áß¿äÇÒ °Å °°½À´Ï´Ù.
Âü°í·Î, MRI·Î surveillance¸¦ ÇÑ ¾Æ»êº´¿ø ¿¬±¸ °á°ú¿¡¼´Â 2cm À̳»¿¡¼ °£¾ÏÀÌ ¹ß°ßµÇ´Â ºñÀ²Àº 74.4% ¿´½À´Ï´Ù (Kim SY et al., JAMA Oncol 2016).
1) EsoTODAY - Esophageal diseases
2) SmallTODAY - Small bowel diseases
3) ColonTODAY
- Colorectal diseases
4) Dr. Sinn's LiverTODAY - Liver diseases
© ¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ »ï¼º¼¿ïº´¿ø ¼Òȱ⳻°ú ½Åµ¿Çö